0000000000022760

AUTHOR

Juan F. Vázquez-costa

showing 15 related works from this author

Clinical spectrum of BICD2 mutations.

2020

Background and purpose Mutations in the BICD2 gene cause autosomal dominant lower extremity-predominant spinal muscular atrophy 2A (SMALED2A), a condition that is associated with a specific pattern of thigh and calf muscle involvement when studied by magnetic resonance imaging (MRI). Patients may present minor clinical sensory impairment, but objective sensory involvement has yet to be demonstrated. Methods We collected clinical data from 11 patients from five different families carrying mutations in BICD2. Genetic diagnosis was achieved using gene panel testing and skin biopsies were taken from two patients to study the epidermal nerve fiber density. Results In the studied patients, three …

Pathologymedicine.medical_specialtyWeaknessSensory systemNerve fiberBICD2 Charcot-Marie-Tooth hereditary motor neuropathy muscle magnetic resonance imaging spinal muscular atrophyThighmedicine.disease_causeMuscular Atrophy Spinal03 medical and health sciences0302 clinical medicineCharcot-Marie-Tooth DiseasemedicineHumans030212 general & internal medicineMuscle SkeletalMutationLegmedicine.diagnostic_testbiologybusiness.industryMagnetic resonance imagingSpinal muscular atrophymedicine.diseasebiology.organism_classificationMagnetic Resonance ImagingMediusmedicine.anatomical_structureNeurologyMutationNeurology (clinical)medicine.symptombusinessMicrotubule-Associated Proteins030217 neurology & neurosurgery
researchProduct

Clinical profile of motor neuron disease patients with lower urinary tract symptoms and neurogenic bladder

2017

Introduction: Lower urinary tract symptoms (LUTS) are frequent in motor neuron disease (MND) patients, but clinical factors related to them are unknown. We describe differences in LUTS among MND phenotypes and their relationship with other clinical characteristics, including prognosis. Methods: For this study, we collected clinical data of a previously published cohort of patients diagnosed with classical amyotrophic lateral sclerosis (cALS), progressive muscular atrophy (PMA) or primary lateral sclerosis (PLS) with and without LUTS. Familial history was recorded and the C9ORF72 expansion was analysed in the entire cohort Patients were followed-up for survival until August 2016. Results: Fi…

Malemedicine.medical_specialtyNeurogenic bladder030232 urology & nephrologyDiseaseMuscular Atrophy Spinal03 medical and health sciencesSex Factors0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsC9orf72Primary lateral sclerosisInternal medicinemedicineHumansLower urinary tract symptomsMotor neuron diseaseMotor Neuron DiseaseUrinary Bladder NeurogenicFamily historyAmyotrophic lateral sclerosisAgedPrimary Lateral SclerosisC9orf72 Proteinbusiness.industryAmyotrophic Lateral SclerosisMiddle AgedProgressive muscular atrophyPrognosismedicine.diseaseAmyotrophic lateral sclerosisSurvival AnalysisSurgeryUrodynamicsCross-Sectional StudiesPhenotypeNeurologyProgressive muscular atrophyAmyotrophic lateral sclerosis Lower urinary tract symptoms Motor neuron disease Neurogenic bladder Primary lateral sclerosis Progressive muscular atrophy UrodynamicsMultivariate AnalysisCohortFemaleNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Ultrasound-guided lumbar puncture for nusinersen administration in spinal muscular atrophy patients.

2020

Background and purpose The purpose was to report the results of ultrasound-guided lumbar puncture for the administration of nusinersen in spinal muscular atrophy (SMA) patients with complex spines. Methods Eighteen SMA patients (five children, five adolescents and eight adults) with either severe scoliosis or spondylodesis were evaluated for ultrasound-guided lumbar puncture. Ultrasound was performed with a 3.5 MHz transducer to guide a 22 gauge × 15 mm needle, which was placed in the posterior lumbar space following a parasagittal interlaminar approach. Results Twelve patients had undergone spinal instrumentation (nine growing rods and three spinal fusion) whilst the other six showed sever…

Adultmusculoskeletal diseasesmedicine.medical_specialtyAdolescentlumbar puncture nusinersen spinal muscular atrophy ultrasound complex spine and intrathecalmedicine.medical_treatmentOligonucleotidesSpinal PunctureMuscular Atrophy Spinal03 medical and health sciences0302 clinical medicineLumbarmedicineHumans030212 general & internal medicineAdverse effectChildUltrasonography Interventionalmedicine.diagnostic_testbusiness.industryLumbar punctureUltrasoundSpinal muscular atrophySMA*medicine.diseaseSurgeryNeurologySpinal fusionNusinersenNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Treatment of patients with spinal muscular atrophy 5q: Towards a new protocol.

2021

Protocol (science)medicine.medical_specialtybusiness.industrySHAM CONTROLMEDLINESpinal muscular atrophymedicine.diseaseNUSINERSENMuscular Atrophy SpinalText miningPhysical medicine and rehabilitationHumansMedicineNeurology. Diseases of the nervous systembusinessRC346-429
researchProduct

Early Referral to an ALS Center Reduces Several Months the Diagnostic Delay: A Multicenter-Based Study.

2020

Objective: To analyze those factors contributing to the diagnostic delay in ALS.Methods: Consecutive ALS patients were categorized as those studied in departmental hospitals and those studied in a referral ALS center. Demographic and clinical variables, together with data of the diagnostic pathway were collected. Multivariable models were used to assess their effect in the time between symptoms onset and the first neurologist visit (time symptoms-neurologist), in the time between the first neurologist visit and the diagnosis (time neurologist-diagnosis) and in the diagnostic delay.Results: 166 ALS patients with a median diagnostic delay of 11.53 months (IQR: 6.68, 15.23) were included. The …

Pediatricsmedicine.medical_specialtyamyotrophic lateral sclerosisALS UnitClinical variablesReferrallcsh:RC346-42903 medical and health sciences0302 clinical medicinemental disordersmedicine030212 general & internal medicineAmyotrophic lateral sclerosislcsh:Neurology. Diseases of the nervous systemOriginal Researchdiagnostic timelinesbusiness.industryUpper motor neuronmedicine.diseasediagnostic delaynervous system diseasesdiagnostic pathwaymedicine.anatomical_structureNeurologyReferral centerBulbar onsetProgression rateNeurology (clinical)business030217 neurology & neurosurgeryEarly referralFrontiers in neurology
researchProduct

Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia

2021

AbstractAccording to the degree of upper and lower motor neuron degeneration, motor neuron diseases (MND) can be categorized into amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) or progressive muscular atrophy (PMA). Although several studies have addressed the prevalence and incidence of ALS, there is a high heterogeneity in their results. Besides this, neither concept has been previously studied in PLS or PMA. Thus, the objective of this study was to estimate the prevalence and incidence of MND, (distinguishing ALS, PLS and PMA), in the Spanish regions of Catalonia and Valencia in the period 2011–2019. Two population-based Spanish cohorts were used, one from Catalonia …

MaleMalalties neuromuscularsGene ExpressionSuperoxide Dismutase-10302 clinical medicinePrevalence030212 general & internal medicineAmyotrophic lateral sclerosisEstimation theoryPrimary Lateral Sclerosismedia_commonMotor neuronsMotor Neuronseducation.field_of_studyMultidisciplinaryIncidenceIncidence (epidemiology)QRMiddle AgedProgressive muscular atrophyNeuromuscular diseasesmedicine.anatomical_structureNeurones motoresNeurologyMedicineFemaleRiskSciencemedia_common.quotation_subjectPopulationBiologyArticleMuscular Atrophy Spinal03 medical and health sciencesmedicineHumansMotor Neuron DiseaseEspanyaEstimació Teoria de l'educationAgedEstimationSelection biasMotor neurons -- DiseasesModels StatisticalC9orf72 ProteinAmyotrophic Lateral SclerosisMotor neuronmedicine.diseaseRisk factorsSpainNeurones motores -- MalaltiesMutationBiomarkers030217 neurology & neurosurgeryDemography
researchProduct

Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy

2021

ABSTRACTObjectiveTo assess in adult spinal muscular atrophy (SMA) patients the construct validity and responsiveness of several outcome measures.MethodsPatients older than 15 years and followed-up at least for 6 months, between October 2015 and August 2020, with one motor function scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Bedside functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) were also collected when available. Correlations and regression models were performed to evaluate the construct validity. The monthly slopes of change were use…

medicine.medical_specialtybusiness.industryConstruct validityRegression analysisSpinal muscular atrophymedicine.diseaseSMA*Physical medicine and rehabilitationmedicine.anatomical_structureRating scaleFloor effectmedicineUpper limbAmyotrophic lateral sclerosisbusiness
researchProduct

Phenotypical features of two patients diagnosed with PHARC syndrome and carriers of a new homozygous mutation in the ABHD12 gene.

2018

Abstract PHARC (Polyneuropathy, Hearing loss, Ataxia, Retinitis pigmentosa and Cataracts) (MIM# 612674 ) is an autosomal recessive neurodegenerative disease caused by mutations in the ABHD12 gene. We evaluated two Spanish siblings affected with pes cavus, sensorimotor neuropathy, hearing loss, retinitis pigmentosa and juvenile cataracts in whom the genetic test of ABHD12 revealed a novel homozygous frameshift mutation, c.211_223del (p.Arg71Tyrfs*26). The earliest clinical manifestation in these patients was a demyelinating neuropathy manifested with a Charcot-Marie-Tooth phenotype over three decades. Progressive hearing loss, cataracts and retinitis pigmentosa appeared after the age of 30. …

AdultMaleARLID12 genecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAtaxiagenetic structuresHearing lossUsher syndromeCharcot-Marie-Tooth diseaseCataractFrameshift mutation03 medical and health sciencesPolyneuropathies0302 clinical medicineCataractsRetinitis pigmentosaotorhinolaryngologic diseasesmedicineHumansMuscle SkeletalDeaf-blindnessbusiness.industryPHARCBrainmedicine.diseaseDermatologyMagnetic Resonance Imagingeye diseasesMonoacylglycerol LipasesPedigreePhenotypeNeurologySpainMutation030221 ophthalmology & optometryAtaxiasense organsNeurology (clinical)medicine.symptombusinessUsher syndromePolyneuropathy030217 neurology & neurosurgeryRetinitis PigmentosaRetinopathyJournal of the neurological sciences
researchProduct

Phenotype and natural history of inherited neuropathies caused byHSJ1c.352+1G>A mutation

2015

Mutations in the HSJ1 ( Heat-Shock Protein J1 ) gene, also called DNAJB2 (DnaJ (Hsp40) homologue, subfamily B, member 2), have been recently described as a cause of hereditary neuropathies. The HSJ1 c.352+1G>A mutation in homozygote state has been reported as the causative mutation in a single family with autosomal recessive distal hereditary motor neuropathy (dHMN).1 Since then, two other families with different HSJ1 mutations have been described: one with a dHMN phenotype and the other with a Charcot-Marie-Tooth disease type 2 (CMT2) phenotype.2 We identified the HSJ1 c.352+1G>A mutation in 10 patients who underwent long-lasting follow-up. We describe their phenotype and clinical evolutio…

AdultMale0301 basic medicineNeural ConductionCell Cycle ProteinsNeurological examinationDisease03 medical and health sciencessymbols.namesake0302 clinical medicineCharcot-Marie-Tooth DiseasemedicineHumansGeneHeat-Shock ProteinsExome sequencingAdaptor Proteins Signal TransducingGenetic testingGeneticsSanger sequencingmedicine.diagnostic_testbusiness.industryNuclear ProteinsMiddle AgedPhenotypePsychiatry and Mental healthPhenotype030104 developmental biologySpainMutationMutation (genetic algorithm)symbolsFemaleSurgeryNeurology (clinical)Hereditary Sensory and Motor Neuropathybusiness030217 neurology & neurosurgeryJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Clinical and neuroimaging characterization of two C9orf72-positive siblings with amyotrophic lateral sclerosis and schizophrenia

2015

C9orf72 expansion is the main genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and has also been found in a wide spectrum of other neurodegenerative diseases (...

0301 basic medicineNeuroimaging03 medical and health sciences0302 clinical medicineNeuroimagingC9orf72mental disordersHumansMedicineAmyotrophic lateral sclerosisC9orf72 Proteinbusiness.industrySiblingsAmyotrophic Lateral SclerosisProteinsMiddle Agedmedicine.diseaseC9orf72 Protein030104 developmental biologyNeurologySchizophreniaMutationMutation (genetic algorithm)SchizophreniaFemaleNeurology (clinical)businessNeuroscience030217 neurology & neurosurgeryFrontotemporal dementiaAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
researchProduct

Clinical and genetic characteristics of 21 Spanish patients with biallelic pathogenic SPG7 mutations.

2021

Spastic paraplegia type 7 (SPG7) is one of the most common hereditary spastic paraplegias. SPG7 mutations most often lead to spastic paraparesis (HSP) and/or hereditary cerebellar ataxia (HCA), frequently with mixed phenotypes. We sought to clinically and genetically characterize a Spanish cohort of SPG7 patients. Patients were recruited from our HCA and HSP cohorts. We identified twenty-one patients with biallelic pathogenic SPG7 mutations. Mean age at onset was 37.4 years (SD ± 14.3). The most frequent phenotype was spastic ataxia (57%), followed by pure spastic paraplegia (19%) and complex phenotypes (19%). Isolated patients presented with focal or multifocal dystonia, subclinical myopat…

medicine.medical_specialtyNeurogeneticsCompound heterozygosityGastroenterologyInternal medicinemedicineSpasticHumansMyopathySubclinical infectionDystoniaCerebellar ataxiabusiness.industrySpastic Paraplegia HereditaryMetalloendopeptidasesmedicine.diseasenervous system diseasesOptic AtrophyPhenotypeNeurologyMutationATPases Associated with Diverse Cellular ActivitiesNeurology (clinical)medicine.symptombusinessSpastic paraplegia type 7Journal of the neurological sciences
researchProduct

Moral reasoning and moral conflict in patients of the amyotrophic lateral sclerosis – Frontotemporal dementia spectrum

2020

The aim of this study was to investigate the moral reasoning and moral conflict in patients of the amyotrophic lateral sclerosis – frontotemporal dementia (ALSFTD) spectrum. Ten ALS patients without cognitive impairment, 10 ALS patients with cognitive or behavioral impairment, 10 ALSFTD patients and 23 controls were examined with neuropsychological and behavioral tests as well as with a set of eight well -designed moral dilemmas. The responses to the moral dilemmas were used as proxies to evaluate interpersonal moral reasoning. Reactivity to change, reaction time and arousal were used as markers of moral conflict. ALSFTD patients showed more “utilitarian” responses and less moral conflict t…

AdultMaleSocial PsychologyDecision MakingMoral reasoningDevelopmentNeuropsychological TestsMoralsfrontotemporal dementia050105 experimental psychologyConflict Psychological03 medical and health sciencesBehavioral NeuroscienceDisability EvaluationMoral conflict0302 clinical medicineMental ProcessesmedicineReaction TimeHumans0501 psychology and cognitive sciencesIn patientAmyotrophic lateral sclerosishealth care economics and organizationsAgedPsychiatric Status Rating Scalesmoral reasoning05 social sciencesmoral conflictMiddle Agedmedicine.diseaseAmyotrophic lateral sclerosishumanitiesMoral reasoningFemalePsychologyCognition Disorders030217 neurology & neurosurgeryFrontotemporal dementiaFrontotemporal dementiaClinical psychologySocial Neuroscience
researchProduct

Primary lateral sclerosis and hereditary spastic paraplegia in sporadic patients. An important distinction in descriptive studies.

2016

Abstract Differentiating between primary lateral sclerosis and apparently sporadic hereditary spastic paraplegia patients is an important but difficult issue in transversal studies. Consequently, these patients have been indistinctly classified as primary lateral sclerosis or sporadic HSP in different publications, further contributing to the confusion between both diseases. In our opinion, Schule et al have not reliably excluded PLS in their cohort of simplex HSP, what could affect their reported results. We think that a clearer distinction should be made between both diseases and we propose new definitions and criteria to facilitate this differentiation. This article is protected by copyr…

Pediatricsmedicine.medical_specialtybusiness.industryHereditary spastic paraplegiaSpastic Paraplegia Hereditarymedicine.disease03 medical and health sciences0302 clinical medicineNeurologyCohortPhysical therapyMedicineHumans030212 general & internal medicineNeurology (clinical)medicine.symptomAmyotrophic lateral sclerosisMotor Neuron Diseasebusiness030217 neurology & neurosurgeryConfusionPrimary Lateral SclerosisAnnals of neurology
researchProduct

Analysis of the diagnostic pathway and delay in patients with amyotrophic lateral sclerosis in the Valencian Community

2021

Introduction: Amyotrophic lateral sclerosis (ALS) is an insidious, clinically heterogeneous neurodegenerative disease associated with a diagnostic delay of approximately 12 months. No study conducted to date has analysed the diagnostic pathway in Spain. Methods: We gathered data on variables related to the diagnostic pathway and delay for patients diagnosed with ALS between October 2013 and July 2017. Results: The study included 143 patients with ALS (57% men; 68% spinal onset). Patients were diagnosed in public centres in 86% of cases and in private centres in 14%. The mean diagnostic delay was 13.1 months (median 11.7). Patients were examined by neurologists a mean time of 7.9 months afte…

MalePediatricsmedicine.medical_specialtyDelayed DiagnosisDiseaseValencian communityTrayecto diagnósticomedicineHumansIn patientSymptom onsetNeurologistsAmyotrophic lateral sclerosisRC346-429Referral and Consultationbusiness.industryAmyotrophic lateral sclerosis Diagnostic delay Diagnostic pathway Electrophysiological study Esclerosis lateral amiotrófica Estudio electrofisiológico Retraso diagnóstico Trayecto diagnósticoAmyotrophic Lateral SclerosisNeurodegenerative Diseasesmedicine.diseaseRetraso diagnósticoEstudio electrofisiológicoPrivate healthcareFemaleEsclerosis lateral amiotróficaNeurology. Diseases of the nervous systembusinessHealthcare systemEarly referralNeurología (English Edition)
researchProduct

Genetic and constitutional factors are major contributors to substantia nigra hyperechogenicity

2017

9 páginas, 2 figuras, 4 tablas

0301 basic medicineMalemedicine.medical_specialtyMovement disordersScienceSubstantia nigraDiseaseComorbidityArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGenetic Predisposition to DiseaseFamily historyAmyotrophic lateral sclerosisPsychiatryGenetic Association StudiesGenetic testingAgedUltrasonographyMultidisciplinarymedicine.diagnostic_testbusiness.industryQCase-control studyRNeurodegenerative DiseasesMiddle Agedmedicine.diseaseComorbiditySubstantia Nigra030104 developmental biologyCase-Control StudiesMutationMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgeryBiomarkers
researchProduct